Loading clinical trials...
Loading clinical trials...
Phase 1, Dose-Escalation, Open-label, Safety and Pharmacokinetic, First in Human Study of BXQ-350 Administered as a Single Agent by Intravenous Infusion in Adult Patients With Advanced Solid Tumors and Recurrent High-Grade Gliomas
Conditions
Interventions
BXQ-350
Locations
4
United States
University of Kentucky Markey Cancer Center
Lexington, Kentucky, United States
University of New Mexico Cancer Center
Albuquerque, New Mexico, United States
University of Cincinnati Barrett Center
Cincinnati, Ohio, United States
The Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
Start Date
September 1, 2016
Primary Completion Date
June 17, 2019
Completion Date
June 15, 2020
Last Updated
July 22, 2021
NCT00026884
NCT07159659
NCT07213804
NCT07169851
NCT06662786
NCT07191730
Lead Sponsor
Bexion Pharmaceuticals, Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions